Bacterial infection Dx firm raises €18.5m
This article was originally published in Clinica
Executive Summary
A consortium of European venture capital firms have invested €18.5m ($27.1m) of series A financing in German molecular diagnostics start-up Curetis. The Holzgerlingen-based company will use the proceeds to complete development of its first range of products and gain the necessary regulatory approvals to commercialise them. The initial products will focus on diagnosing severe bacterial infections, such as pneumonia. Investors in Curetis include Life Sciences Partners; BioMedPartners; ERP-Startfonds of the KfW Bankengruppe; and aeris CAPITAL, which also provided the company with seed funding.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.